Athersys (ATHX)

Business description

Athersys is a US biotech company developing MultiStem (allogeneic, bone marrow-derived stem cells). A Phase II trial with MultiStem in ischaemic stroke is complete, while further studies in AMI (Phase II) and ARDS (Phase IIa) are planned.

Share price chart

Share chart

Stock data

Market cap.US$87m
Last closeUS$1.05
High / Low (52 weeks)US$3.3 / US$1.0
Stock market listingUS
Forecast net cash (US$m)27
Forecast gearing ratio (%)N/A
SectorPharmaceutical & Healthcare

Price performance

Relative *(2.5)(12.3)(26.3)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Forward Pharma
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab Genticel
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Lifewatch AG Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Quantum Pharmaceuticals Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Theraclion Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Group Tissue Therapies
Tonix Pharmaceuticals Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
UDG Healthcare uniQure NV
Universal Biosensors Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Company Update (NASDAQ:ATHX): Athersys, Inc. Updates on Development Strategy ...

Wed, 21 Oct 2015 12:12:59 GMT

Stock Update (NASDAQ:ATHX): Athersys, Inc.'s MultiStem Promotes Recovery After ...

Thu, 19 Nov 2015 12:45:00 GMT

Company Update (NASDAQ:ATHX): Athersys, Inc. Reports Third Quarter 2015 Results

Thu, 05 Nov 2015 22:07:30 GMT

ATHERSYS ALERT: National Securities Law Firm Announces Investigation of ...

Fri, 17 Apr 2015 16:18:41 GMT

Why Athersys, Inc. Shares Are Soaring Higher Today

Wed, 08 Apr 2015 19:52:30 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2013A 2.4 (24.8) (24.4) (42.34) N/A N/A
2014A 1.6 (29.3) (28.9) (37.26) N/A N/A
2015E 5.5 (25.4) (25.0) (30.80) N/A N/A
2016E 1.7 (30.1) (29.8) (36.25) N/A N/A

Last updated on 18/11/2015

Investment summary

Athersys is developing MultiStem, an allogeneic, bone marrow-derived stem cell product. Results from a 140-patient Phase II study in ischaemic stroke revealed a potential benefit when dosed <36 hours post stroke (vs 3-5 hours with tPA), although the primary/secondary endpoints were not met on an intent-to-treat basis. Athersys is assessing next development steps and is in partnership talks. A Phase II trial with MultiStem in acute myocardial infarction is underway with data expected in H216, and a Phase IIa study for acute respiratory distress syndrome (ARDS) will be initiated soon.

Last updated on 25/11/2015

Industry outlook

MultiStem is an allogeneic (off-the-shelf) product that allows it to be used in both acute and chronic treatment settings, and holds potential to be used across a range of indications. Regenerative medicine is gaining traction and recognition by global regulators (eg accelerated approval pathway in Japan).

Last updated on 25/11/2015

Key management

Gil Van Bokkelen, CEO
William (BJ) Lehmann, President and COO

Company address

Carnegie Avenue
OH 4415-26
United States
+1 216-431-9900
View website